Towards the genetic treatment of β-thalassemia: New disease models, new vectors, new cells

Haematologica

Volumn 93, Issue 3, 2008, Pages 325-330

  Moi, Paolo ^a   Sadelain, Michel ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLOBIN; TRANSCRIPTION FACTOR;

ANEMIA; BETA THALASSEMIA; BONE MARROW TRANSPLANTATION; GENE EXPRESSION; GENE MUTATION; GENE THERAPY; GENETIC TRANSCRIPTION; GLOBIN GENE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SYNTHESIS; IRON OVERLOAD; NONHUMAN; REVIEW; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION;

ANIMALS; BETA-THALASSEMIA; CELL DEDIFFERENTIATION; DISEASE MODELS, ANIMAL; FIBROBLASTS; GENE DELETION; GENE THERAPY; GENES, SYNTHETIC; GENETIC VECTORS; GLOBINS; HUMANS; LENTIVIRUS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, MUTANT STRAINS; MICE, SCID; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; STEM CELL TRANSPLANTATION; TRANSGENES;

EID: 40849126617     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12732     Document Type: Review

References (67)

1. Stamatoyannopoulos G, Nienhuis W, Majerus W, Varmus H. The molecular basis of blood diseases. Philadelphia: Saunders; 1994.
2. Steinberg M, Forget B, Higgs D, Nagel R. Disorders of haemoglobin: genetics, pathophysiology and clinical managment. Cambridge, UK: Cambridge University Press; 2001.
3. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001;2:245-55.
4. Wheatherall D, Clegg J. The thalassemia syndromes. Oxford: Blackwell Scientific Publication; 1981.
5. Cooley T, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925;37:29.
6. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001;38:360-6.
7. Boulad F, Giardina P, Gillio A, Kernan N, Small T, Brochstein J, et al. Bone marrow transplantation for homozygous betathalassemia. The Memorial Sloan-Kettering Cancer Center experience. Ann N Y Acad Sci 1998;850:498-502.
8. Giardini C, Lucarelli G. Bone marrow transplantation in the treatment of thalassemia. Curr Opin Hematol 1994;1:170-6.
9. Lucarelli G, Clift RA, Galimberti M, Angelucci E, Giardini C, Baronciani D, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999;93:1164-7.
10. Leboulch P, Huang GM, Humphries RK, Oh YH, Eaves CJ, Tuan DY, et al. Mutagenesis of retroviral vectors transducing human beta-globin gene and beta-globin locus control region derivatives results in stable transmission of an active transcriptional structure. Embo J 1994; 13: 3065-76.
11. Sadelain M, Wang CH, Antoniou M, Grosveld F, Mulligan RC. Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. Proc Natl Acad Sci U S A 1995;92:6728-32.
12. Skow LC, Burkhart BA, Johnson FM, Popp RA, Popp DM, Goldberg SZ, et al. A mouse model for beta-thalassemia. Cell 1983;34:1043-52.
13. Shehee WR, Oliver P, Smithies O. Lethal thalassemia after insertional disruption of the mouse major adult beta-globin gene. Proc Natl Acad Sci U S A 1993;90:3177-81.
14. Yang B, Kirby S, Lewis J, Detloff PJ, Maeda N, Smithies O. A mouse model for beta 0-thalassemia. Proc Natl Acad Sci U S A 1995;92:11608-12.
15. Lewis J, Yang B, Kim R, Sierakowska H, Kole R, Smithies O, et al. A common human beta globin splicing mutation modeled in mice. Blood 1998;91:2152-6.
16. Rivella S, May C, Chadburn A, Riviere I, Sadelain M. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003;101:2932-9.
17. Jamsai D, Zaibak F, Khongnium W, Vadolas J, Voullaire L, Fowler KJ, et al. A humanized mouse model for a common beta0-thalassemia mutation. Genomics 2005;85:453-61.
18. Jamsai D, Zaibak F, Vadolas J, Voullaire L, Fowler KJ, Gazeas S, et al. A humanized BAC transgenic/knockout mouse model for HbE/beta-thalassemia. Genomics 2006;88:309-15.
19. Vadolas J, Nefedov M, Wardan H, Mansooriderakshan S, Voullaire L, Jamsai D, et al. Humanized beta-thalassemia mouse model containing the common IVSI-110 splicing mutation. J Biol Chem 2006;281:7399-405.
20. Vadolas J, Wardan H, Bosmans M, Zaibak F, Jamsai D, Voullaire L, et al. Transgene copy number-dependent rescue of murine beta-globin knockout mice carrying a 183 kb human beta-globin BAC genomic fragment. Biochim Biophys Acta 2005;1728:150-62.
21. Larochelle A, Vormoor J, Lapidot T, Sher G, Furukawa T, Li Q, et al. Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols. Hum Mol Genet 1995;4: 163-72.
22. Puthenveetil G, Scholes J, Carbonell D, Qureshi N, Xia P, Zeng L, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004;104:3445-53.
23. Bender MA, Gelinas RE, Miller AD. A majority of mice show long-term expression of a human beta-globin gene after retrovirus transfer into hematopoietic stem cells. Mol Cell Biol 1989;9:1426-34.
24. Bodine DM, Karlsson S, Nienhuis AW. Combination of interleukins 3 and 6 preserves stem cell function in culture and enhances retrovirus-mediated gene transfer into hematopoietic stem cells. Proc Natl Acad Sci USA 1989;86:8897-901.
25. Cone RD, Weber-Benarous A, Baorto D, Mulligan RC. Regulated expression of a complete human beta-globin gene encoded by a transmissible retrovirus vector. Mol Cell Biol 1987;7:887-97.
26. Dzierzak EA, Papayannopoulou T, Mulligan RC. Lineagespecific expression of a human beta-globin gene in murine bone marrow transplant recipients reconstituted with retrovirus-transduced stem cells. Nature 1988;331:35-41.
27. Karlsson S, Papayannopoulou T, Schweiger SG, Stamatoyannopoulos G, Nienhuis AW. Retroviral-mediated transfer of genomic globin genes leads to regulated production of RNA and protein. Proc Natl Acad Sci USA 1987; 84:2411-5.
28. Plavec I, Papayannopoulou T, Maury C, Meyer F. A human beta-globin gene fused to the human beta-globin locus control region is expressed at high levels in erythroid cells of mice engrafted with retrovirus-transduced hematopoietic stem cells. Blood 1993;81:1384-92.
29. Chang JC, Liu D, Kan YW. A 36-base-pair core sequence of locus control region enhances retrovirally transferred human beta-globin gene expression. Proc Natl Acad Sci USA 1992;89:3107-10.
30. Novak U, Harris EA, Forrester W, Groudine M, Gelinas R. High-level beta-globin expression after retroviral transfer of locus activation region-containing human beta-globin gene derivatives into murine erythroleukemia cells. Proc Natl Acad Sci USA 1990;87:3386-90.
31. Bulger M, Groudine M. Looping versus linking: toward a model for long-distance gene activation. Genes Dev 1999;13:2465-77.
32. Bulger M, Sawado T, Schubeler D, Groudine M. ChIPs of the beta-globin locus: unraveling gene regulation within an active domain. Curr Opin Genet Dev 2002;12:170-7.
33. de Krom M, van de Corput M, von Lindern M, Grosveld F, Strouboulis J. Stochastic patterns in globin gene expression are established prior to transcriptional activation and are clonally inherited. Mol Cell 2002;9:1319-26.
34. Engel JD, Tanimoto K. Looping, linking, and chromatin activity: new insights into beta-globin locus regulation. Cell 2000;100:499-502.
35. Grosveld F. Activation by locus control regions? Curr Opin Genet Dev 1999;9:152-7.
36. Higgs DR. Do LCRs open chromatin domains? Cell 1998;95:299-302.
37. Levings PP, Bungert J. The human beta-globin locus control region. Eur J Biochem 2002;269:1589-99.
38. Navas PA, Li Q, Peterson KR, Swank RA, Rohde A, Roy J, et al. Activation of the beta-like globin genes in transgenic mice is dependent on the presence of the beta-locus control region. Hum Mol Genet 2002;11:893-903.
39. Rivella S, Lisowski L, Sadelain M. Globin gene transfer: a paradigm for transgene regulation and vector safety. Gene Therapy and Regulation 2003;2:149-75.
40. Ellis J, Pasceri P, Tan-Un KC, Wu X, Harper A, Fraser P, et al. Evaluation of beta-globin gene therapy constructs in single copy transgenic mice. Nucleic Acids Res 1997;25: 1296-302.
41. Emery DW, Morrish F, Li Q, Stamatoyannopoulos G. Analysis of gamma-globin expression cassettes in retrovirus vectors. Hum Gene Ther 1999;10:877-88.
42. Lung HY, Meeus IS, Weinberg RS, Atweh GF. In vivo silencing of the human gamma-globin gene in murine erythroid cells following retroviral transduction. Blood Cells Mol Dis 2000;26:613-9.
43. Ren S, Wong BY, Li J, Luo XN, Wong PM, Atweh GF. Production of genetically stable high-titer retroviral vectors that carry a human gamma-globin gene under the control of the alpha-globin locus control region. Blood 1996;87:2518-24.
44. Sabatino DE, Seidel NE, Aviles-Mendoza GJ, Cline AP, Anderson SM, Gallagher PG, et al. Long-term expression of gamma-globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma-globin gene fused to the ankyrin-1 promoter. Proc Natl Acad Sci USA 2000;97:13294-9.
45. Sabatino DE, Wong C, Cline AP, Pyle L, Garrett LJ, Gallagher PG, et al. A minimal ankyrin promoter linked to a human gamma-globin gene demonstrates erythroid specific copy number dependent expression with minimal position or enhancer dependence in transgenic mice. J Biol Chem 2000; 275:28549-54.
46. Fragkos M, Anagnou NP, Tubb J, Emery DW. Use of the hereditary persistence of fetal hemoglobin 2 enhancer to increase the expression of oncoretrovirus vectors for human gamma-globin. Gene Ther 2005;12:1591-600.
47. Katsantoni EZ, Langeveld A, Wai AW, Drabek D, Grosveld F, Anagnou NP, et al. Persistent gamma-globin expression in adult transgenic mice is mediated by HPFH-2, HPFH-3, and HPFH-6 breakpoint sequences. Blood 2003;102:3412-9.
48. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000;406:82-6.
49. Levasseur DN, Ryan TM, Pawlik KM, Townes TM. Correction of a mouse model of sickle cell disease: lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 2003;102:4312-9.
50. Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, Bouhassira EE, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 2001;294:2368-71.
51. Persons DA, Hargrove PW, Allay ER, Hanawa H, Nienhuis AW. The degree of phenotypic correction of murine beta - thalassemia intermedia following lentiviral-mediated transfer of a human gamma-globin gene is influenced by chromosomal position effects and vector copy number. Blood 2003;101:2175-83.
52. Samakoglu S, Lisowski L, Budak-Alpdogan T, Usachenko Y, Acuto S, Di Marzo R, et al. A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference. Nat Biotechnol 2006; 24: 89-94.
53. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002; 99: 1902-8.
54. Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, Eaves CJ, et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci USA 2002; 99: 14380-5.
55. Lisowski L, Sadelain M. Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in -thalassemic mice. Blood 2007;110:4175-8.
56. Han XD, Lin C, Chang J, Sadelain M, Kan YW. Fetal gene therapy of alpha-thalassemia in a mouse model. Proc Natl Acad Sci USA 2007;104:9007-11.
57. Chang JC, Ye L, Kan YW. Correction of the sickle cell mutation in embryonic stem cells. Proc Natl Acad Sci USA 2006;103:1036-40.
58. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-76.
59. Meissner A, Wernig M, Jaenisch R. Direct reprogramming of genetically unmodified fibroblasts into pluripotent stem cells. Nat Biotechnol 2007;25:1177-81.
60. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol 2007;26:101-6.
61. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-7.
62. Park IH, Zhao R, West JA, Yabuuchi A, Huo H, Ince TA, et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2007;451:141-6.
63. Takahashi K, Okita K, Nakagawa M, Yamanaka S. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007;2:3081-9.
64. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
65. Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K, et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007;448:318-24.
66. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-20.
67. Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007;318:1920-3.